| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 826.2 | 702.8 | 652.8 |
| Other income | 2.5 | 0.8 | 0.1 |
| Total income | 828.8 | 703.6 | 652.9 |
| Profit before exceptional items & tax | 109.3 | 71.3 | 60.4 |
| Exceptional items | 0.0 | -2.1 | 0.0 |
| Profit before tax | 109.3 | 69.2 | 60.4 |
| Net profit | 82.8 | 50.1 | 45.2 |
| Operating margin | 13.2% | 9.8% | 9.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +83.20% |
|---|---|
| Net profit, quarter on quarter | +65.30% |
| Revenue, year on year | +26.60% |
| Operating profit, year on year | +77.10% |
| Operating profit, quarter on quarter | +51.50% |
BSE results filing, NSE: AARTIDRUGS. Figures extracted from the filing.
Aarti Drugs Ltd: key numbers
- Share price
- ₹466.30
- Market cap
- ₹4,256 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 22.3×Sector 41.3×
- Promoter holding
- 54.07%-0.36% QoQ
- FII holding
- 2.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 826.2 Cr (+27% YoY), EBITDA Rs 137.9 Cr (16.6% margin, +370 bps), PAT Rs 82.8 Cr (+83%). Specialty chemicals nearly doubled; formulations grew 58%.
Aarti Drugs Results Update
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Aarti Drugs Board Meeting Date
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
Aarti Drugs Other Announcement
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs Other Announcement
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Aarti Drugs Management Change
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.